Cerus, BioOne Corp. sales and marketing update

Cerus will reacquire from BioOne commercial rights to Intercept Blood System for plasma and platelets in Japan, China, Taiwan, South Korea, Thailand, Vietnam and Singapore. Cerus said the move allows it to pursue a different business strategy and potential partnerships for all three of its Intercept Blood System programs, which also includes a system for red blood cells. Cerus markets its Intercept Blood Systems for plasma and platelets in the EU, Middle East, Russia and other countries to inactivate blood-borne pathogens in donated blood components intended for transfusion. The systems for plasma and platelets, which use amotosalen light-activated compound to inactivate pathogens, are in Phase III testing in the U.S., while the system for red blood cells is in Phase I testing in the U.S. ...